Effect of intravenous corticosteroid on ex vivo leukotriene generation by blood leucocytes of normal and asthmatic patients

Pauline P Hood, Timothy P Cotter, John F Costello, Anthony P Sampson

Abstract

Background—The cysteinyl-leukotrienes (LTc₄, LTD₄, LTE₄) are critical bronchoconstrictor and eosinophilotactic mediators in asthma while LTB₄ is a potent neutrophil chemoattractant. Glucocorticosteroids are front line anti-inflammatory treatment for asthma but the evidence that they reduce leukotriene (LT) synthesis in vivo is poor.

Methods—In a randomised, double blind, placebo controlled, crossover trial immunonasays were used to measure ex vivo synthesis of LTC₄ and LTB₄ by calcium ionophore stimulated blood leucocytes and bronchoalveolar lavage (BAL) cells of eight normal subjects and eight patients with mild allergic asthma 4–6 hours after intravenous administration of a single 100 mg dose of methylprednisolone.

Results—Ionophore stimulated synthesis of LTC₄ (but not LTB₄) in blood granulocytes tended to be higher in asthmatic subjects (mean 9.7 ng/10⁶ cells) than in normal subjects (4.2 ng/10⁶ cells; p = 0.08) and intravenous methylprednisolone reduced synthesis of LTC₄ (but not LTB₄) to normal levels (2.9 ng/10⁶ cells; 95% CI for the reduction 1.0 to 12.5 ng/10⁶ cells; p = 0.03). In blood mononuclear cells methylprednisolone reduced LTC₄ synthesis in asthmatic subjects from 1.26 to 0.79 ng/10⁶ cells (95% CI for the reduction 0.26 to 0.79, p = 0.014) and tended to reduce LTC₄ synthesis in normal subjects from 1.51 to 0.86 ng/10⁶ cells (p = 0.08). Methylprednisolone also significantly reduced synthesis of LTB₄ in mononuclear cells from both subject groups (p = 0.014). It had no effect on LT synthesis in BAL cells from either group nor on LT levels in BAL fluid.

Conclusions—Intravenous methylprednisolone can reduce synthesis of leukotrienes in blood granulocytes and mononuclear cells within six hours of a single intravenous dose.

(Keywords: leukotrienes; corticosteroids; asthma)

Leukotrienes (LT) are products of arachidonic acid synthesised by the 5-lipoxygenase (5-LO) pathway. The cysteinyl-LTs (LTc₄, LTD₄, and LTE₄) are potent constrictors of human bronchial smooth muscle and cause mucus hypersecretion and airway oedema. Cysteinyl-LTs are also potent and specific chemoattractants for human eosinophils in vivo. Concentrations of cysteinyl-LTs in the bronchoalveolar lavage (BAL) fluid and urine of asthmatic subjects rise after allergen challenge and during acute asthma exacerbations. Clinical trials of specific anti-leukotriene drugs have confirmed the major contribution of cysteinyl-LTs to bronchocstriction and eosinophilia in asthma. LTE₄ is a potent leucocyte chemoattractant in vivo but there is relatively little evidence for a role in asthma.

Glucocorticosteroids are a mainstay of asthma treatment due to their modulation of the expression of pro-inflammatory cytokines and adhesion molecules. They reduce the synthesis of leukotrienes in vitro by upregulating the expression of lipocortin which inhibits liberation of arachidonic acid from membrane phospholipids by phospholipase A₂. However, it is not clear whether corticosteroids suppress LT synthesis in vivo. Treatment of normal and asthmatic subjects with oral or inhaled corticosteroids for up to 14 days did not reduce urinary excretion of LTE₄ or BAL fluid levels of LTB₄. However, in normal and asthmatic subjects treatment with oral prednisone for seven days significantly suppressed reduced ex vivo release of LTB₄ by BAL cells.

Long term oral corticosteroid treatment of asthmatic subjects may also abolish ex vivo synthesis of LTB₄ in ionophore stimulated blood granulocytes and mononuclear cells.

The clinical benefits of systemic corticosteroids on admission rate and peak expiratory flow in acute severe asthma begin to be observed at about four hours. Suppression of LTB₄ synthesis in alveolar macrophages is apparent within 13 hours of treatment with oral prednisone in subjects with nocturnal asthma. No previous studies have investigated ex vivo LT synthesis within 12 hours of a single dose of systemic corticosteroid, or at any time after intravenous administration. Furthermore, most studies have focused on ex vivo LTB₄ synthesis whereas the role of cysteinyl-LTs in asthma is much better established. We hypothesised that systemic corticosteroids may suppress LTB₄ and/or LTC₄ synthesis in blood and/or airway leucocytes within 4–6 hours. A double blind, placebo controlled, randomised, crossover trial of the effects of an intravenous bolus dose of 100 mg methylprednisolone on ex vivo synthesis of LTs in BAL cells and in blood granulocytes and mononuclear cells and on BAL fluid LT levels was therefore carried out in eight mild allergic asthmatic patients and eight normal subjects.

Department of Respiratory Medicine, King's College School of Medicine & Dentistry, London SE5 9PJ, UK
P P Hood
T P Cotter
J F Costello

University Medicine, Southampton General Hospital, Southampton, SO16 6YD, UK
A P Sampson

Correspondence to: Dr A P Sampson

Received 1 February 1999
Returned to authors 4 May 1999
Revised manuscript received 19 August 1999
Accepted for publication 24 August 1999

Thorax 1999;54:1075–1082

1075
Methods

PATIENT RECRUITMENT

Permission for the study was obtained from King’s College Hospital Ethics committee and all subjects gave informed written consent to take part. All subjects were non-smokers. Eight patients with mild atopic asthma and eight non-atopic normal subjects were recruited. Asthmatic patients (4M, 4F; median age 25 years, range 23–30) had positive skin prick tests (weal >2 mm) to at least two common allergens and geometric mean serum IgE of 245 IU/ml (range 135–446). Asthmatic patients had an appropriate clinical history and bronchial hyperreactivity to inhaled methacholine (PC20 <8 mg/ml) but were stable at the time of study with a median forced expiratory volume in one second (FEV1) of 97% (range 83–122). Asthmatic patients used inhaled β2 agonist bronchodilators but had not used theophylline, cromones, or oral or inhaled corticosteroids for at least six weeks before the study. Normal subjects (3M, 5F; median age 22.5 years, range 20–30) had no history of chronic respiratory disease, provided normal lung function tests (median FEV1, 94%, range 86–106) with methacholine PC20 >16 mg/ml, and had negative skin prick tests with total serum IgE of 9 IU/ml (range 4–25; p < 0.001 versus asthmatic patients).

BRONCHOSCOPY AND BRONCHOALVEOLAR LAVAGE

In a double blind, randomised, crossover manner, normal and asthmatic subjects received an intravenous bolus dose of 144 mg methylprednisolone sulpetanate (Upjohn; 100 mg methylprednisolone equivalents) and a placebo (sterile 0.9% saline solution) at least two weeks apart. Four hours after each intravenous dose 100 ml of peripheral venous blood was taken for differential cell counting by a blinded observer and for leucocyte isolation. Subjects immediately underwent bronchoscopy using an Olympus BF P20D flexible fibreoptic bronchoscope as described.18 Bronchoalveolar lavage was performed with three 60 ml aliquots of warmed sterile saline (0.9%; 37°C) containing inulin (0.1 mM) and BAL fluid was separated from cells by centrifugation. The supernatant was concentrated 10-fold by evaporation and was considered significant.

Radioimmunoassays for LTβ and LTC4 were performed as described previously19 using tritiated H-LTβ, and H-LTC4, (NEN Dupont, Hounslow, UK) and standard LTβ and LTC4 (Cascade Chemicals, Reading, UK). The rabbit polyclonal antibody for cysteinyl-LTs was a gift from Professor B Peskar (University of Graz, Austria) and the LTβ antisemur was a gift from Dr A W Ford-Hutchinson (Merck-Frost Canada).

STATISTICAL ANALYSIS

Comparisons between placebo and methylprednisolone treatments were performed by paired tests for non-parametric data (Wilcoxon sign rank sum test) and between subject groups by unpaired tests for non-parametric data (Mann-Whitney U test). A p value of <0.05 was considered significant.

ASSAY OF MEXTHYLPRDNIHOSLONE IN BAL FLUID AND PLASMA

Concentrations of methylprednisolone in plasma were measured by UV absorption at 254 nm after dichloromethane extraction and straight phase HPLC using a dichloromethane/heptane/acetic acid/ethanol solvent mixture (600:350:10:35; 2 ml/min) on a Zorbax silica column (250 × 4.6 mm). Methylprednisolone in BAL fluid was purified by HPLC on a Hypersil BDS 3 μM C8 column (5 cm) in acetonitrile/N-methylmorpholine (35:65; 1 ml/min) and quantified by mass spectrometry (Perkin-Elmer Sciex API III).
Corticosteroids and leukotriene generation in asthma

Results

METHYLPREDNISOLONE LEVELS IN BAL FLUID AND PLASMA

Four hours after intravenous dosing the mean (SE) plasma concentration of methylprednisolone in asthmatic subjects (315 (35) ng/ml) was not significantly different from that in normal subjects (333 (30) ng/ml), both values equating to approximately 0.9 µM. Uncorrected concentrations of methylprednisolone in BAL fluid tended to be slightly lower in asthmatic subjects (5.0 (1.0) ng/ml) than in normal subjects (7.8 (1.0) ng/ml, p = 0.06). After correction for variable dilution by instilled lavage fluid using the inulin technique methylprednisolone concentrations in the original epithelial lining fluid (ELF) were estimated as 0.14 µM in asthmatic subjects and 0.22 µM in normal subjects, approximately one fifth those in plasma.

EFFECT OF INTRAVENOUS METHYLPREDNISOLONE ON BAL CELL AND BLOOD LEUCOCYTE DIFFERENTIAL COUNTS

After placebo there were no significant differences in total leucocyte counts between normal subjects (mean 5.9 million cells/ml) and asthmatic patients (6.2 million cells/ml), or in the mean counts of neutrophils, monocytes, or eosinophils (table 1). In normal subjects intravenous methylprednisolone more than doubled blood counts of neutrophils (p<0.01) and tended to reduce the mean counts of lymphocytes and monocytes (p<0.1). In patients with atopic asthma methylprednisolone significantly increased neutrophil counts (p<0.02) and reduced counts of lymphocytes (p<0.02) and monocytes (p<0.02). In both patient groups eosinophil counts tended to be lower after methylprednisolone but this did not reach statistical significance.

After placebo BAL cell populations were predominantly macrophages in normal subjects (92.1% of total cells) and asthmatic patients (86.5%), with the remainder being epithelial cells, lymphocytes, neutrophils, and eosinophils (table 2). Total and differential cell counts were not significantly different between the subject groups after placebo, and methylprednisolone did not change the total counts of BAL cells recovered or the proportions of any BAL cell type in either subject group.

Table 1 Peripheral blood leucocyte counts (×10⁹/ml) in normal (n = 8) and allergic asthmatic (n = 8) subjects four hours after intravenous administration of 144 mg methylprednisolone sublendeptanate (100 mg methylprednisolone equivalents) and placebo (saline)

<table>
<thead>
<tr>
<th></th>
<th>Placebo</th>
<th>Methylprednisolone</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asthmatic subjects:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total leucocytes</td>
<td>5.9 (5.0–8.3)</td>
<td>8.8 (5.5–12.2)</td>
</tr>
<tr>
<td>Neutrophils</td>
<td>3.1 (2.3–4.1)</td>
<td>8.4 (4.1–10.5)**</td>
</tr>
<tr>
<td>Eosinophils</td>
<td>0.08 (0.0–0.63)</td>
<td>0.01 (0.0–0.07)</td>
</tr>
<tr>
<td>Monocytes</td>
<td>0.39 (0.05–0.63)</td>
<td>0.07 (0.06–0.07)</td>
</tr>
<tr>
<td>Lymphocytes</td>
<td>2.5 (1.3–3.82)</td>
<td>1.2 (0.3–1.8)</td>
</tr>
<tr>
<td>Normal subjects:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total leucocytes</td>
<td>6.2 (4.2–10.3)</td>
<td>7.9 (4.9–11.3)</td>
</tr>
<tr>
<td>Neutrophils</td>
<td>3.7 (1.6–6.6)</td>
<td>7.0 (4.2–9.9)*</td>
</tr>
<tr>
<td>Eosinophils</td>
<td>0.09 (0.0–0.25)</td>
<td>0.01 (0.01–0.10)</td>
</tr>
<tr>
<td>Monocytes</td>
<td>0.19 (0.05–0.41)</td>
<td>0.05 (0.01–0.10)*</td>
</tr>
<tr>
<td>Lymphocytes</td>
<td>2.3 (1.9–2.4)</td>
<td>0.82 (0.22–1.36)</td>
</tr>
</tbody>
</table>

Values are arithmetic mean (range). *p<0.01 versus placebo (Wilcoxon). There were no significant differences between the subject groups after placebo.

Methylprednisolone significantly increased neutrophil counts in both subject groups and significantly reduced monocyte and lymphocyte counts in the asthmatic subjects.

EFECT OF INTRAVENOUS METHYLPREDNISOLONE ON LEUKOTRIENE SYNTHESIS IN BLOOD POLYMORPHONUCLEAR LEUCOCYTES

In seven normal subjects PMNL isolated from blood four hours after placebo treatment synthesised mean (SE) LTC₄ levels of 4.21 (1.22) ng/10⁶ cells when stimulated with A23187 (2 µM) for 20 minutes (fig 1). Intravenous methylprednisolone had no effect on ex vivo LTC₄ synthesis by the PMNL of normal subjects (3.89 (1.76) ng/10⁶ cells, p>0.5).

In eight asthmatic patients LTC₄ synthesis by PMNL after placebo (9.67 (2.62) ng/10⁶ cells) tended to be higher than in the normal subjects (95% confidence interval for difference –1.1 to 12.0; p = 0.08). LTC₄ synthesis by asthmatic PMNL was significantly reduced by methylprednisolone to 2.91 (0.67) ng/10⁶ cells (p = 0.03; fig 1). The mean reduction was 6.76 ng/10⁶ cells (95% CI 1.01 to 12.52).

LTB₄ synthesis was similar in the PMNL of normal and asthmatic subjects after placebo (4.2 (0.9) and 5.7 (0.8) ng/10⁶ cells, respectively; p>0.3). Methylprednisolone did not significantly alter LTB₄ synthesis in PMNL from either the normal subjects (6.2 (1.0) ng/10⁶ cells; p>0.2) or the asthmatic patients (7.2 (1.1) ng/10⁶ cells; p>0.2).

Table 2 Differential bronchoalveolar lavage (BAL) cell counts (% of total cells) in normal (n = 8) and allergic asthmatic (n = 8) subjects four hours after intravenous administration of 144 mg methylprednisolone sublendeptanate (100 mg methylprednisolone equivalents) and placebo (saline)

<table>
<thead>
<tr>
<th></th>
<th>Placebo</th>
<th>Methylprednisolone</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asthmatic subjects:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Macrophages</td>
<td>92.1 (87.3–94.4)</td>
<td>92.7 (79.0–98.0)</td>
</tr>
<tr>
<td>Neutrophils</td>
<td>0.5 (0.2–1.1)</td>
<td>1.1 (0.1–4.2)*</td>
</tr>
<tr>
<td>Eosinophils</td>
<td>0.5 (0.2–1.1)</td>
<td>0.2 (0.0–0.3)</td>
</tr>
<tr>
<td>Lymphocytes</td>
<td>3.4 (0.6–6.2)</td>
<td>2.8 (0.9–6.4)</td>
</tr>
<tr>
<td>Epithelial cells</td>
<td>4.3 (1.3–8.1)</td>
<td>3.2 (0.7–13.2)</td>
</tr>
<tr>
<td>Normal subjects:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Macrophages</td>
<td>86.5 (81.7–95.5)</td>
<td>87.5 (61.0–94.6)</td>
</tr>
<tr>
<td>Neutrophils</td>
<td>0.17 (0.0–3.3)</td>
<td>0.6 (0.1–1.4)</td>
</tr>
<tr>
<td>Eosinophils</td>
<td>0.3 (0.1–0.6)</td>
<td>0.2 (0.0–1.4)</td>
</tr>
<tr>
<td>Lymphocytes</td>
<td>2.5 (1.3–6.6)</td>
<td>3.8 (1.0–5.2)</td>
</tr>
<tr>
<td>Epithelial cells</td>
<td>5.3 (3.0–14.9)</td>
<td>10.1 (1.5–37)</td>
</tr>
</tbody>
</table>

Values are median (range). There were no significant differences between the subject groups in total or differential BAL cell counts after placebo, and methylprednisolone had no significant effect on total or differential BAL cell counts in either subject group.

EFECT OF INTRAVENOUS METHYLPREDNISOLONE ON LEUKOTRIENE SYNTHESIS IN BLOOD MONONUCLEAR CELLS

In eight normal subjects mononuclear cells isolated from blood four hours after placebo treatment synthesised mean LTC₄ levels of 1.51 (0.30) ng/10⁶ cells when stimulated with calcium ionophore A23187 (2 µM) for 20 minutes (fig 2). Treatment with intravenous methylprednisolone tended to reduce ex vivo LTC₄ synthesis to 0.86 (0.26) ng/10⁶ cells but this did not reach statistical significance (p = 0.07). The mean fall was 0.64 ng/10⁶ cells (95% CI –0.2 to 1.48). In eight asthmatic patients LTC₄ synthesis did not reach statistical significance (p>0.5).
synthesis by MNC after placebo was 1.26 (0.09) ng/10^6 cells, not significantly different from normal MNC, and this was significantly reduced after treatment with methylprednisolone (0.79 (0.12) ng/10^6 cells, p = 0.014; fig 2). The mean fall was 0.48 ng/10^6 cells (95% CI 0.26 to 0.79).

Intravenous methylprednisolone was also effective in mononuclear cells in reducing ex vivo synthesis of LTB_4. In eight normal subjects A23187 stimulated MNC generated 3.13 (0.46) ng/10^6 cells of LTB_4 after placebo, which was reduced to 1.54 (0.14) ng/10^6 cells after methylprednisolone (p = 0.014; fig 2). The mean fall was 1.59 ng/10^6 cells (95% CI 0.64 to 2.54). In eight asthmatic patients ex vivo synthesis of LTB_4 by MNC was 2.75 (0.33) ng/10^6 cells after placebo, not significantly different from normal MNC, and this was significantly reduced to 1.30 (1.0) ng/10^6 cells after methylprednisolone (p = 0.014).
cells after methylprednisolone (p = 0.014; fig 2). The mean fall was 1.44 ng/10⁶ cells (95% CI 0.72 to 2.15).

EFFECT OF INTRAVENOUS METHYLPREDNISOLONE ON BAL FLUID LEVELS OF LEUKOTRIENES AND ON EX VIVO SYNTHESIS OF LEUKOTRIENES BY BAL CELLS

Assessment of the degree of dilution of ELF by instillation of sterile saline during BAL was performed by the inulin method as described elsewhere.18 The proportion of ELF in recovered BAL fluid was similar (7–12%) in the normal and asthmatic groups, justifying direct comparisons of LT levels in BAL fluid between the groups. BAL fluid levels of LTC₄ after placebo were significantly higher in asthmatic patients (30.6 (11.7) pg/ml, n = 8) than in normal subjects (9.7 (1.0) pg/ml, n = 8, p = 0.027, Mann-Whitney, 95% CI for the difference 2.4 to 26.4 pg/ml). However, methylprednisolone did not reduce BAL fluid levels of LTC₄ either in the asthmatic patients (25.1 (6.9) pg/ml, p>0.2) or in the normal subjects (9.0 (0.7) pg/ml, p>0.3) compared with placebo (fig 3).

BAL fluid levels of LTB₄ after placebo were not significantly different in asthmatic patients (189 (29.5) pg/ml) and normal subjects (147 (15.0) pg/ml; p = 0.09, Mann-Whitney). Methylprednisolone did not affect BAL fluid levels of LTB₄ either in the asthmatic patients (199 (21.0) pg/ml, p=0.3) or in the normal subjects (123 (19.0) pg/ml, p=0.2; fig 3).

BAL cells stimulated in vitro with calcium ionophore A23187 for 20 minutes generated LTC₄ and LTB₄. In normal subjects intravenous methylprednisolone did not alter A23187 stimulated synthesis of LTC₄ (0.84 (0.13) ng/10⁶ cells) compared with placebo (0.81 (0.07) ng/10⁶ cells) nor the synthesis of LTB₄ (9.31 (3.1) ng/10⁶ cells) compared with placebo (6.7 (2.0) ng/10⁶ cells). In asthmatic patients ex vivo synthesis of LTC₄ (0.62 (0.01) ng/10⁶ cells) and LTB₄ (4.0 (0.4) ng/10⁶ cells) after placebo was similar to that observed in the normal subjects and was similarly unaffected by intravenous methylprednisolone (0.62 (0.02) ng/10⁶ cells and 12.2 (4.6) ng/10⁶ cells, respectively, p>0.05).

Discussion

The mechanisms by which systemic corticosteroids produce rapid clinical improvements in acute severe asthma are unclear. It is also unclear whether inhibition of leukotriene synthesis contributes to the anti-inflammatory effects of corticosteroids either in acute severe asthma or in chronic persistent asthma. Several multiple dose studies in asthmatic and normal subjects have failed to show an effect of corticosteroids on urinary LTE₄ and BAL fluid LTB₄ levels in persistent asthma.10–13 To explore the early effects of systemic corticosteroids we investigated the effects of a single dose of intravenous corticosteroid on LT synthesis at a time point (4–6 hours), much earlier than any previous single dose study but similar to the time course of clinical improvement seen in acute severe asthmatics following systemic corticosteroid therapy.15–16 As well as in BAL cells and BAL fluid, LT synthesis was examined in blood polymorphonuclear leucocytes (PMNL) and mononuclear cells (MNC). Our results show for the first time that the enhanced capacity of blood PMNL to generate LTC₄ in mild allergic asthmatic subjects is significantly reduced within six hours of intravenous administration of methylprednisolone. Furthermore,
methylprednisolone markedly reduced ex vivo synthesis of both LTC₄ and LTB₄ in blood MNC from asthmatic patients and normal subjects. This rapid anti-inflammatory activity may contribute to the early therapeutic effects of systemic corticosteroids on lung function and airway inflammation in acute severe asthma.

The most profound changes seen following methylprednisolone administration were marked reductions in the ex vivo A23187-stimulated synthesis of LTs by blood leukocytes. Methylprednisolone suppressed the synthesis of the potent bronchonstrictor and eosinophilotactic mediator LTC₄ in blood PMNL of asthmatic patients (p<0.03; fig 1). In normal subjects baseline synthesis of LTC₄ by blood PMNL was only about half that in asthmatic PMNL (p = 0.08) and it was not significantly reduced by methylprednisolone. These LTC₄ data are best explained by group differences in 5-LO pathway activity within the eosinophil subpopulation, as the capacity of human neutrophils to generate LTC₄ is negligible.²³ The data are unlikely to be explained by the tendency for eosinophil percentages within PMNL preparations to fall after methylprednisolone (table 1) as these falls did not reach statistical significance and occurred in both subject groups while the fall in LTC₄ synthesis was only seen in the asthmatic subjects. The trend for increased capacity of blood eosinophils from asthmatic subjects to synthesise LTC₄ agrees with significant results in previous studies¹⁹ ²⁰ and may be due to in vivo priming by eosinophilotactic cytokines implicated in allergic inflammation such as interleukin (IL-)3 and IL-5.²² The ability of methylprednisolone to reduce LTC₄ synthesis in eosinophils in asthmatic subjects may prevent a vicious cycle of eosinophil migration and LTC₄ synthesis. In contrast, the overwhelming source of LTB₄ generated by PMNL preparations is the neutrophil;²⁵ the lack of effect of methylprednisolone on LTB₄ synthesis in PMNL of both subject groups (p>0.2) is consistent with the resistance of the LT pathway in blood neutrophils to suppression by corticosteroids in vitro.²⁶ However, the relatively low statistical power of the study (n = 8) means that we cannot entirely exclude a small effect of methylprednisolone on the LTB₄ pathway.

In blood MNC, even though there were no differences in baseline LT synthesis between the normal and asthmatic groups, synthesis of LTC₄, and LTB₄, was significantly reduced in both groups within six hours of intravenous methylprednisolone (fig 2). The primary source of both LTs in human MNC preparations is likely to be the monocyte. The reduced LTB₄ and LTC₄ synthesis cannot be due to corticosteroid induced alterations in the proportion of monocytes within the MNC preparations as the ratio of monocytes to lymphocytes remained the same after methylprednisolone in both subject groups (table 1). The dual inhibition of LTB₄ and LTC₄ synthesis by methylprednisolone acts at a proximal site in the 5-LO pathway in MNC, not at the level of the terminal enzymes LTA₄ hydrolase or LTC₄ synthase. This is supported by the finding that abolition of ex vivo LT synthesis in blood leukocytes following treatment of asthmatics for more than one year with systemic deflazacort is related to reductions in PLA₂ and 5-LO activity.¹⁴ Our data suggest that these changes are initiated in MNC within six hours of exposure to a single dose of a systemic corticosteroid.

Methylprednisolone concentrations in prelavage ELF four hours after intravenous injection were estimated by correcting mass spectrometry values in BAL fluid by an inulin dilution factor.¹⁵ The concentration of methylprednisolone achieved in ELF (approximately 0.2 µM) is sufficient to inhibit in vitro synthesis of LTC₄ and LTB₄ in rat alveolar macrophages by approximately 80%.²³ Despite this, in both subject groups intravenous methylprednisolone failed to reduce ex vivo synthesis of LTB₄ or LTC₄ by BAL cells (approximately 90% macrophages) compared with placebo. This result contrasts with those of multiple dose corticosteroid studies which show reductions in spontaneous and zymosan stimulated synthesis of LTB₄, ex vivo in macrophage-rich BAL cells from asthmatic and normal asthmatic subjects.¹⁰ ¹³ One explanation is that the number of subjects in this study (n = 8) was too low to detect a reduction in LT synthesis in BAL cells. However, since significant reductions were observed in PMNL and MNC, it is more likely that the intravenous route of administration allowed more rapid access of methylprednisolone to the circulating leucocyte pool than to the cells in the airway lumen. Our data are also consistent with the relatively modest suppression of LTB₄ synthesis observed in vitro in alveolar macrophages from normal and asthmatic subjects after culture with methylprednisolone (1 µM) for 16 hours;²² and with a study showing no inhibition of A23187 stimulated synthesis of LTB₄ in alveolar macrophages of normal and non-nocturnal asthmatic subjects 13 hours after a single dose of prednisone.¹⁷ Together, these data suggest that in normal and mild non-nocturnal asthmatic subjects a single systemic dose of corticosteroid has no effect on 5-LO pathway activity in airway macrophages within 13 hours. The effects of corticosteroids on BAL cell synthesis in multiple dose studies may reflect subtle long term changes in macrophage phenotype or activation status within the airway.²⁸ The lack of effect of methylprednisolone on LT synthesis in BAL cells is supported by the lack of change in LTB₄ and LTC₄ in BAL fluid (fig 3). In agreement with other workers,³ we found that, after placebo, levels of LTC₄ were significantly higher in the BAL fluid of allergic asthmatic patients than in normal subjects. The basal elevation in BAL fluid LTC₄ in the asthmatic subjects was more than threefold but it is possible that lack of statistical power in this study may have precluded the detection of a relatively modest effect of methylprednisolone on BAL cells. However, in a study showing no inhibition of LTB₄ synthesis by methylprednisolone may indicate that, in normal and mild stable asthmatic
Corticosteroids and leukotriene generation in asthma

Ex vivo LT synthesis by intravenous methylprednisolone thus appears to be most evident in blood eosinophils and monocytes, although smaller effects on BAL cells and fluid cannot be excluded due to the relatively small number of subjects studied. We have recently linked deterioration in lung function in mild mono-allergic asthmatic subjects during the birch pollen season to specific increases in 5-LO pathway enzyme expression in bronchial biopsies which were entirely explained by influx of eosinophils and monocytes. The present data suggest that blood eosinophils and monocytes are early cellular targets of systemic steroids.

The mechanisms by which corticosteroids modulate LT synthesis in blood leucocytes are unclear. Corticosteroids are thought to modulate gene expression by interaction of the steroid receptor complex with glucocorticoid response elements (GRE) in gene promoters or by interaction with nuclear transcription factors such as NF-κB as GREs are regulated directly or indirectly by steroids include a range of pro-inflammatory cytokines, adhesion molecules, and enzymes. Corticosteroids may modulate LT synthesis by regulating expression of 5-LO pathway enzymes as the FLAP gene promoter contains a GRE while the 5-LO promoter has an NF-κB recognition sequence. Our use of calcium ionophore A23187 as a stimulus rather than a receptor dependent stimulus such as zymosan allows the site of action of methylprednisolone to be localised to the 5-LO pathway itself and not to changes in cell surface receptor density, and the potency of A23187 maximises the sensitivity of the model. Paradoxical upregulation by corticosteroids of 5-LO and/or FLAP expression has been reported in human monocytes, neutrophils, and eosinophils although such changes do not necessarily alter cellular capacity for LT synthesis. Inhibition of LT synthesis in alveolar macrophages by multiple dose glucocorticoid therapy is associated with induction of the PLA2 inhibitor lipocortin-1 but this appears not to occur in blood granulocytes or monocytes in vivo. Recent evidence suggests fluticasone inhibits LTC4 synthesis in human eosinophils in vitro by blocking translocation of cPLA2 to the nuclear envelope. Such a mechanism is consistent with dual inhibition of LTβ, and LTC4 synthesis reported in MNC in the present study and with suppression of prostanoid synthesis reported by others.

Overall, the effects of corticosteroids on LT synthesis in vivo depend on the populations and activation status of leucocytes in the airway and other compartments, and on the balance between the induction of lipocortin expression, modulation of PLA2, 5-LO, and/or FLAP activity and expression, and changes in the density of membrane receptors for immunological stimuli. Our study uses useful insights into the net result of these conflicting factors within the first six hours of systemic steroid administration, showing that the most pronounced early effect is a reduction in the capacity of PMNL in asthmatic blood to generate LTC4 and in the capacity of blood monocytes from both patient groups to synthesise LTC4 and LTβ. These changes may contribute to early improvements in lung function and to the suppression of airway eosinophilic inflammation following systemic corticosteroid therapy in acute asthma.

This work was supported by the Upjohn Company and by the Frances & Augustus Newman Foundation. The authors thank Dr A W Ford-Hutchinson (Merck-Frost Canada) and Professor B Peras (University of Graz, Austria) for generous gifts of leukotriene antagonists.


Effect of intravenous corticosteroid on ex vivo leukotriene generation by blood leucocytes of normal and asthmatic patients

Pauline P Hood, Timothy P Cotter, John F Costello and Anthony P Sampson

Thorax 1999 54: 1075-1082
doi: 10.1136/thx.54.12.1075

Updated information and services can be found at:
http://thorax.bmj.com/content/54/12/1075

These include:

References
This article cites 32 articles, 12 of which you can access for free at:
http://thorax.bmj.com/content/54/12/1075#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
Asthma (1782)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/